Technicals Say Integra LifeSciences Holdings Corporation (IART) Is A Hold

Integra LifeSciences Holdings Corporation (NASDAQ:IART) finished Friday with a subtraction of -$0.13 to close at $70.82, a downside of -0.18 percent. An average of 257,400 shares of common stock have been traded in the last five days. There was a gain of $3.14 in the past week, and it reached a new high 32 times over the past 12 months. The last 20 days have seen an average of 293,860 shares traded, while the 50-day average volume stands at 339,970.

IART stock has decreased by -2.09% in the last month. The company shares reached their 1-month lowest point of $65.86 on 10/13/21. With the stock rallying to its 52-week high on 04/28/21, shares of the company touched a low of $42.12 and a high of $77.40 in 52 weeks. It has reached a new high 20 times so far this year and achieved 9.09% or $5.90 in price. In spite of this, the price is down -8.50% from the 52-week high.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Insider Transactions

50 days have passed since Integra LifeSciences Holdings Corporation (IART) last reported insider trading activity. Arduini Peter J, who is President & CEO, most recently acquired $46,605 shares at $75.75 per share on Sep 03. In this transaction, the insider spent $3,530,459. President & CEO, Arduini Peter J, disposed of 71,829 shares at a price of $75.97 on Sep 02. The insider now owns more than $5,456,662 worth of shares. Prior to that, EVP & President, CSS McBreen Michael J. went on to Sale 4,000 shares at $71.22 each on Aug 06. An amount of $284,886 was transacted.

Valuation Metrics

Integra LifeSciences Holdings Corporation (IART) has a trailing price-to-earnings (P/E) ratio of 29.31, which compares with the 26.30 for the broader industry and 33.43 for the sector. In the last five years, Integra LifeSciences Holdings Corporation’s PE ratio has ranged between 180.19 and 26.96. The stock’s beta is 1.24. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.94, the price-to-book (PB) ratio at 3.81, and the price-to-cash flow ratio at 21.11.

The quick ratio of Integra LifeSciences Holdings Corporation for the three months ended June 29 was 2.20, and the current ratio was 3.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.95 and a total debt to equity ratio of 0.98 for the quarter ending June 29. Integra LifeSciences Holdings Corporation’s EBITDA margin for the year ending June 29 is 24.02%, while its operating margin for the same period stands at 15.00%. Its gross profit as reported stood at $851.03 million compared to revenue of $1.37 billion.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Integra LifeSciences Holdings Corporation’s return on assets was 5.70%. For the broader industry, ROE averaged 3.96 over the past year.

Earnings Surprise

For the three-month period that ended June 29, Integra LifeSciences Holdings Corporation had $823.21 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $35.07 million in the quarter, while revenues of $45.39 million were grew 101.06%. The analyst consensus anticipated Integra LifeSciences Holdings Corporation’s latest quarter earnings to come in at $0.66 per share, but it turned out to be $0.79, a 19.70% surprise. For the quarter, EBITDA amounted to $83.46 million. Shareholders own equity worth $84.58 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Integra LifeSciences Holdings Corporation (IART) price momentum. RSI 9-day as of the close on 22 October was 63.55%, suggesting the stock is Neutral, with historical volatility in this time frame at 10.34%.

As of today, IART’s price is $69.59 +4.64% or $3.14 from its 5-day moving average. IART is currently trading -1.88% lower than its 20-day SMA and +6.03% higher than its 100-day SMA. However, the stock’s current price level is -0.17% below the SMA50 and +7.56% above the SMA200.

The stochastic %K and %D were 82.48% and 71.62%, respectively, and the average true range (ATR) was 1.79. With the 14-day stochastic at 70.96% and the average true range at 1.81, the RSI (14) stands at 56.53%. The stock has reached 2.11 on the 9-day MACD Oscillator while the 14-day reading was at 2.14.

Analyst Ratings

BTIG Research downgraded Integra LifeSciences Holdings Corporation (NASDAQ: IART) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Integra LifeSciences Holdings Corporation (IART) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell IART, while 6 suggest investors hold. There are 2 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.

What is IART’s price target for the next 12 months?

Analysts predict a range of price targets between $55.00 and $88.00, with a median target of $78.00. Taking a look at these predictions, the average price target given by analysts for Integra LifeSciences Holdings Corporation (IART) stock is $77.45.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Videos

Related Videos

Related Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

592

100% free. stop anytime no spam